{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T18:24:20Z","timestamp":1763663060697,"version":"3.45.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001718","name":"Netherlands Organization for International Cooperation in Higher Education","doi-asserted-by":"publisher","award":["101005142"],"award-info":[{"award-number":["101005142"]}],"id":[{"id":"10.13039\/501100001718","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ejps.2025.107332","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T09:50:44Z","timestamp":1760694644000},"page":"107332","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Exposure-response analysis of oral and intravenous imatinib in critically ill patients with COVID-19 acute respiratory distress syndrome"],"prefix":"10.1016","volume":"215","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7954-6580","authenticated-orcid":false,"given":"M.M.","family":"Said","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0311-1262","authenticated-orcid":false,"given":"A.M.","family":"Braam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5547-5578","authenticated-orcid":false,"given":"E.","family":"Duijvelaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4697-691X","authenticated-orcid":false,"given":"J.R.","family":"Schippers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7452-1867","authenticated-orcid":false,"given":"L.","family":"Atmowihardjo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9617-1020","authenticated-orcid":false,"given":"J.","family":"Twisk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5371-0346","authenticated-orcid":false,"given":"H.J.","family":"Bogaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5138-7784","authenticated-orcid":false,"given":"E.L.","family":"Swart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6211-1791","authenticated-orcid":false,"given":"J.","family":"Aman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9602-3407","authenticated-orcid":false,"given":"I.H.","family":"Bartelink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2025.107332_bib0002","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S2213-2600(21)00237-X","article-title":"Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial","volume":"9","author":"Aman","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.ejps.2025.107332_bib0003","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1161\/CIRCULATIONAHA.112.134304","article-title":"Effective Treatment of Edema and Endothelial Barrier Dysfunction With Imatinib","volume":"126","author":"Aman","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ejps.2025.107332_bib0004","article-title":"Efficacy and safety of intravenous imatinib in COVID-19 ARDS: a randomized, double-blind, placebo-controlled clinical trial","volume":"27","author":"Atmowihardjo","year":"2023","journal-title":"Crit. Care (Fullerton)"},{"key":"10.1016\/j.ejps.2025.107332_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2023.106418","article-title":"Pharmacokinetics and pharmacodynamics of imatinib for optimal drug repurposing from cancer to COVID-19","volume":"184","author":"Baalbaki","year":"2023","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.ejps.2025.107332_bib0006","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/psp4.12718","article-title":"Elevated acute phase proteins affect pharmacokinetics in COVID-19 trials: Lessons from the CounterCOVID - imatinib study","volume":"10","author":"Bartelink","year":"2021","journal-title":"CPT. Pharmacomet. Syst. Pharmacol."},{"key":"10.1016\/j.ejps.2025.107332_bib0007","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/myc.13570","article-title":"Contribution of voriconazole N-oxide plasma concentration measurements to voriconazole therapeutic drug monitoring in patients with invasive fungal infection","volume":"66","author":"Boglione-Kerrien","year":"2023","journal-title":"Mycoses."},{"key":"10.1016\/j.ejps.2025.107332_bib0008","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/fcp.12007","article-title":"Therapeutic drug monitoring of imatinib in chronic myeloid leukemia: experience from 1216 patients at a centralized laboratory","volume":"27","author":"Bouchet","year":"2012","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2025.107332_bib0009","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00780-2022","article-title":"Immunomodulation and endothelial barrier protection mediate the association between oral imatinib and mortality in hospitalised COVID-19 patients","volume":"60","author":"Brabander","year":"2022","journal-title":"Eur. Respirat. J."},{"key":"10.1016\/j.ejps.2025.107332_bib0010","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ejca.2021.08.033","article-title":"Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy","volume":"157","author":"Clarke","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejps.2025.107332_bib0011","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/leu.2009.88","article-title":"Pharmacokinetic\/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia","volume":"23","author":"Cortes","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.ejps.2025.107332_bib0012","doi-asserted-by":"crossref","first-page":"6073","DOI":"10.1158\/1078-0432.CCR-05-2596","article-title":"Pharmacokinetic-Pharmacodynamic Relationships of Imatinib and Its Main Metabolite in Patients with Advanced Gastrointestinal Stromal Tumors","volume":"12","author":"Delbaldo","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejps.2025.107332_bib0013","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO.2008.20.4818","article-title":"Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable\/Metastatic Gastrointestinal Stromal Tumors","volume":"27","author":"Demetri","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejps.2025.107332_bib0014","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-44986-w","article-title":"Longitudinal plasma proteomics reveals biomarkers of alveolar-capillary barrier disruption in critically ill COVID-19 patients","volume":"15","author":"Duijvelaar","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejps.2025.107332_bib0015","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jchromb.2009.04.045","article-title":"Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry","volume":"877","author":"Haouala","year":"2009","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.ejps.2025.107332_bib0016","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ejps.2025.107332_bib0017","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.cmet.2022.01.008","article-title":"Imatinib and methazolamide ameliorate COVID-19-induced metabolic complications via elevating ACE2 enzymatic activity and inhibiting viral entry","volume":"34","author":"Li","year":"2022","journal-title":"Cell Metab."},{"key":"10.1016\/j.ejps.2025.107332_bib0018","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40262-023-01213-x","article-title":"Pharmacokinetic Alterations Associated with Critical Illness","volume":"62","author":"Morales Castro","year":"2023","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2025.107332_bib0019","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40262-023-01213-x","article-title":"Pharmacokinetic Alterations Associated with Critical Illness","volume":"62","author":"Morales Castro","year":"2023","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2025.107332_bib0020","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1136\/postgradmedj-2020-138577","article-title":"COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment","volume":"97","author":"Parasher","year":"2020","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.ejps.2025.107332_bib0021","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.bpa.2020.12.011","article-title":"COVID-19-associated acute respiratory distress syndrome (CARDS): Current knowledge on pathophysiology and ICU treatment A narrative review","volume":"35","author":"Pfortmueller","year":"2021","journal-title":"Best Pract. Res. Clin. Anaesthesiol."},{"key":"10.1016\/j.ejps.2025.107332_bib0022","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"109","author":"Picard","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ejps.2025.107332_bib0023","doi-asserted-by":"crossref","first-page":"L1294","DOI":"10.1152\/ajplung.00031.2015","article-title":"Imatinib attenuates inflammation and vascular leak in a clinically relevant two-hit model of acute lung injury","volume":"309","author":"Rizzo","year":"2015","journal-title":"Am. J. Physiol.-Lung Cellul. Mol. Physiol."},{"key":"10.1016\/j.ejps.2025.107332_bib0024","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/psp4.13299","article-title":"Disease-Drug-Drug Interaction of Imatinib in COVID-19 ARDS: A Pooled Population Pharmacokinetic Analysis","volume":"14","author":"Said","year":"2025","journal-title":"CPT. Pharmacomet. Syst. Pharmacol."},{"key":"10.1016\/j.ejps.2025.107332_bib0025","unstructured":"SmPC glivec. https:\/\/www.geneesmiddeleninformatiebank.nl\/ords\/f?p=111:3::SEARCH:::P0_DOMAIN,P0_LANG,P3_RVG1:H,NL,71822. Accessed 3 Oct 2023."},{"key":"10.1016\/j.ejps.2025.107332_bib0026","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/FTD.0b013e31823cdec9","article-title":"The Role of Therapeutic Drug Monitoring of Imatinib in Patients with Chronic Myeloid Leukemia and Metastatic or Unresectable Gastrointestinal Stromal Tumors","volume":"34","author":"Teng","year":"2012","journal-title":"Ther. Drug Monit."},{"issue":"23","key":"10.1016\/j.ejps.2025.107332_bib0001","first-page":"2526","article-title":"Acute Respiratory Distress Syndrome: The Berlin Definition","volume":"307","year":"2012","journal-title":"JAMa"},{"key":"10.1016\/j.ejps.2025.107332_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104866","article-title":"Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection","volume":"181","author":"Venisse","year":"2020","journal-title":"Antiv. Res."},{"key":"10.1016\/j.ejps.2025.107332_bib0028","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/jac\/dkw349","article-title":"Voriconazole metabolism is influenced by severe inflammation: a prospective study","volume":"72","author":"Veringa","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejps.2025.107332_bib0029","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-2125.2006.02719.x","article-title":"Population pharmacokinetics of imatinib and the role of \u03b11-acid glycoprotein","volume":"62","author":"Widmer","year":"2006","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2025.107332_bib0030","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1038\/sj.bjc.6604355","article-title":"Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability","volume":"98","author":"Widmer","year":"2008","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejps.2025.107332_bib0031","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41423-023-00985-3","article-title":"A SARS-CoV-2-specific CAR-T-cell model identifies felodipine, fasudil, imatinib, and caspofungin as potential treatments for lethal COVID-19","volume":"20","author":"Xia","year":"2023","journal-title":"Cell Mol. Immunol."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098725003306?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098725003306?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T18:12:08Z","timestamp":1763662328000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098725003306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":31,"alternative-id":["S0928098725003306"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107332","relation":{},"ISSN":["0928-0987"],"issn-type":[{"type":"print","value":"0928-0987"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exposure-response analysis of oral and intravenous imatinib in critically ill patients with COVID-19 acute respiratory distress syndrome","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107332","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107332"}}